191. Werner syndrome
3 clinical trials, 4 drugs (DrugBank: 3 drugs), 1 drug target gene, 5 drug target pathways
Searched query = "Werner syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04512963 (ClinicalTrials.gov) | August 24, 2020 | 6/8/2020 | Phase I Study of Progerinin in Healthy Volunteers | A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) Study Including a Food Interaction Study, Followed by a Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Profile of Progerinin in Healthy Volunteers | Hutchinson-Gilford Progeria Syndrome;Werner Syndrome | Drug: Progerinin;Drug: Placebo | PRG Science & Technology Co., Ltd. | Amarex Clinical Research | Recruiting | 18 Years | 45 Years | All | 56 | Phase 1 | United States |
| 2 | JPRN-jRCTs031190141 | 27/11/2019 | 27/11/2019 | Cross-over trial to verify safety and effectiveness of nicotinamide riboside and pterostilbene for patients with Werner syndrome | Prospective, single-center, cross-over trial to verify safety and effectiveness of nicotinamide riboside and pterostilbene for patients with Werner syndrome - EMPOWER | Werner syndrome Werner syndrome;C16.320.925 / C18.452.284.960 | Subjects ingest oral capsules of NRPT (nicotinamide riboside and pterostilbene) once daily (total daily dose: nicotinamide riboside 500 mg and pterostilbene 100mg) and placebo capsules for 6 months each in a randomly determined order. | Yokote Koutaro | NULL | Recruiting | >= 20age old | Not applicable | Both | 30 | Japan | |
| 3 | NCT00004815 (ClinicalTrials.gov) | May 1992 | 24/2/2000 | Descriptive Study of Recombinant Human Insulin-Like Growth Factor for Osteoporosis in Werner's Syndrome | Werner's Syndrome | Drug: growth hormone | National Center for Research Resources (NCRR) | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);University of Texas | Completed | N/A | N/A | Both | 1 | N/A | NULL |